AcquisitionOther
Avalo Therapeutics, Inc. acquired Anti-IL-1
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Avalo Therapeutics, Inc. -> Anti-IL-1 · $185 Million
AlmataBio was founded to identify, acquire, and accelerate the development of clinically meaningful therapies, and we are proud of the contribution of the talented AlmataBio team to this mission.
Open source record (SEC) ↗